Burden of illness among patients at high risk versus low risk for major cardiovascular events

References

• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171. Erratum in: Circulation 2007;115:e172
   PubMed Web of Science ®Google Scholar
• Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics. Circulation 2006; 113: e85-151. Erratum in: Circulation 2006;113:e696 and Circulation 2006;114:e630
   PubMed Web of Science ®Google Scholar
• Sui X, Lamonte MJ, Blair SN. Cardiorespiratory fitness as a predictor of nonfatal cardiovascular events in asymptomatic women and men. Am J Epidemiol 2007;165:1413-1423
   PubMed Web of Science ®Google Scholar
• Thom TJ, Kannel WB, Silbershatz H, et al. Cardiovascular disease in the United States and preventive approaches. In: Fuster V, Alexander RW, O’Rourke RA, eds. Hurst’s The Heart, Arteries and Veins, 10th edn. New York, NY: McGraw-Hill, 2001
   Google Scholar
• Minino AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006;54:1-49
   Google Scholar
• Nichols GA, Bell TJ, Pedula KL, et al. Medical care costs among patients with established cardiovascular disease. Am J Manag Care 2010;16:e86-93
   PubMed Web of Science ®Google Scholar
• Thorpe KE, Florence CS, Howard DH, et al. The impact of obesity on rising medical spending. Health Aff (Millwood) 2004;Suppl web exclusives:W4–480-486
   Google Scholar
• DeFrances CJ, Podgornik MN. 2004 National hospital discharge survey. Adv Data 2006;371:1-19
   PubMedGoogle Scholar
• Hollenberg NK, Sever PS. The past, present and future of hypertension management: a potential role for AT1-receptor antagonists. J Renin Angiotensin Aldosterone Syst 2000;1:5-10
   PubMedGoogle Scholar
• Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst 2000;1:11-17
   PubMedGoogle Scholar
• Burnier M, Maillard M. Angiotensin II receptor antagonists: where do we stand? IDrugs 2000;3:304-309
   PubMedGoogle Scholar
• Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657
   PubMed Web of Science ®Google Scholar
• Ohkubo N, Matsubara H, Nozawa Y, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997;96:3954-3962
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-1377
   PubMed Web of Science ®Google Scholar
• Navalkar S, Parthasarathy S, Santanam N, et al. Irbesartan, an angiotensin type I receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001;37:440-444
   PubMed Web of Science ®Google Scholar
• Greenberg BH. Role of angiotensin receptor blockers in heart failure: not yet RESOLVD. Circulation 1999;100:1032-1034
   PubMed Web of Science ®Google Scholar
• Dickstein K. Angiotensin II antagonists are superior to ACE-I; David vs Goliath. Eur J Heart Fail 2000;2:235-236
   PubMed Web of Science ®Google Scholar
• Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-992
   PubMed Web of Science ®Google Scholar
• Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153. Erratum in: N Engl J Med 2000;342:1376 and N Engl J Med 2000;342:748
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372. Erratum in: Circulation 2006;113:e847
   PubMed Web of Science ®Google Scholar
• The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
   PubMed Web of Science ®Google Scholar
• Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Last accessed April 3, 2009
   Google Scholar
• SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA, Copyright 1999-2001
   Google Scholar
• Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002;106:388-391
   PubMed Web of Science ®Google Scholar
• Kozak LJ, DeFrances CJ, Hall MJ. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Stat 2006;162:1-209
   Google Scholar
• Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-1115
   PubMed Web of Science ®Google Scholar
• Bloom BS, Tibi-Lévy Y, Harari A, et al. Direct medical care costs of unstable angina pectoris in a defined population. J Manag Care Pharm 1999;5:39-44
   Google Scholar
• Javitz HS, Ward MM, Watson JB, et al. Cost of illness of chronic angina. Am J Manag Care 2004;10:S358-369
   Web of Science ®Google Scholar
• Etemad LR, McCollam PL. Predictors of high-cost managed care patients with acute coronary syndrome. Curr Med Res Opin 2005;21:1977-1984
   PubMed Web of Science ®Google Scholar
• Kahn R, Robertson RM, Smith R, et al. The Impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008;118:576-585
   PubMed Web of Science ®Google Scholar